Is TVGN or SNTI more profitable?

Tevogen Bio's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Senti Biosciences N/A -1,629.80% -119.72%

Does the media favor TVGN or SNTI?

In the previous week, Tevogen Bio had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Senti Biosciences. Tevogen Bio's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SNTI or MGX?

In the previous week, Senti Biosciences and Senti Biosciences both had 2 articles in the media. Senti Biosciences' average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EDSA or SNTI more profitable?

Edesa Biotech's return on equity of -560.22% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Senti Biosciences N/A -1,629.80% -119.72%

Do analysts rate BCTX or SNTI?

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is BCTX or SNTI more profitable?

Briacell Therap's return on equity of -153.53% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Senti Biosciences N/A -1,629.80% -119.72%

Does the media refer more to BCTX or SNTI?

In the previous week, Briacell Therap had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Briacell Therap and 2 mentions for Senti Biosciences. Briacell Therap's average media sentiment score of 0.34 beat Senti Biosciences' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IZTC or SNTI?

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better earnings & valuation, IZTC or SNTI?

Invizyne Technologies has higher earnings, but lower revenue than Senti Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Senti Biosciences $55K 178.04 -$61.44M -$1.77 N/A

Is IZTC or SNTI more profitable?

Invizyne Technologies' return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Senti Biosciences N/A -1,629.80% -119.72%

Senti Biosciences (SNTI) Competitors

$0.31 -0.01 (-2.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-0.13%)

As of 10/9/2026 07:59 PM Eastern

Compare

SNTI vs. TVGN, MGX, EDSA, BCTX, and IZTC

Should you buy Senti Biosciences stock or one of its competitors? Senti Biosciences's main competitors and comparable companies include Tevogen Bio (TVGN), Metagenomi (MGX), Edesa Biotech (EDSA), Briacell Therap (BCTX), and Invizyne Technologies (IZTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Senti Biosciences compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 1,374.93%. Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

25.7% of Senti Biosciences shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tevogen Bio's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Senti Biosciences	N/A	-1,629.80%	-119.72%

In the previous week, Tevogen Bio had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Tevogen Bio and 2 mentions for Senti Biosciences. Tevogen Bio's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio has higher earnings, but lower revenue than Senti Biosciences. Tevogen Bio is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Senti Biosciences	$55K	178.04	-$61.44M	-$1.77	N/A

Tevogen Bio has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Summary

Senti Biosciences beats Tevogen Bio on 10 of the 14 factors compared between the two stocks.

How does Senti Biosciences compare to Metagenomi?

Senti Biosciences (NASDAQ:SNTI) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 3,080.66%. Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 500.00%. Given Senti Biosciences' higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Senti Biosciences has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$55K	178.04	-$61.44M	-$1.77	N/A
Metagenomi	$25.21M	1.50	-$87.87M	-$2.49	N/A

In the previous week, Senti Biosciences and Senti Biosciences both had 2 articles in the media. Senti Biosciences' average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Senti Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Metagenomi	-384.61%	-63.65%	-44.52%

Senti Biosciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Senti Biosciences beats Metagenomi on 8 of the 12 factors compared between the two stocks.

How does Senti Biosciences compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Edesa Biotech currently has a consensus target price of $5.00, indicating a potential upside of 42.45%. Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Senti Biosciences had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Senti Biosciences and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Edesa Biotech	Neutral
Senti Biosciences	Neutral

Edesa Biotech's return on equity of -560.22% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Edesa Biotech has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edesa Biotech has higher earnings, but lower revenue than Senti Biosciences. Edesa Biotech is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Senti Biosciences	$55K	178.04	-$61.44M	-$1.77	N/A

Summary

Senti Biosciences beats Edesa Biotech on 8 of the 13 factors compared between the two stocks.

How does Senti Biosciences compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Briacell Therap has higher earnings, but lower revenue than Senti Biosciences. Briacell Therap is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Senti Biosciences	$55K	178.04	-$61.44M	-$1.77	N/A

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Briacell Therap has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Briacell Therap had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Briacell Therap and 2 mentions for Senti Biosciences. Briacell Therap's average media sentiment score of 0.34 beat Senti Biosciences' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Briacell Therap's return on equity of -153.53% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Summary

Senti Biosciences beats Briacell Therap on 11 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Senti Biosciences had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Senti Biosciences and 0 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Senti Biosciences	Neutral

Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 3,080.66%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Invizyne Technologies' return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Senti Biosciences	N/A	-1,629.80%	-119.72%

Invizyne Technologies has higher earnings, but lower revenue than Senti Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Senti Biosciences	$55K	178.04	-$61.44M	-$1.77	N/A

Summary

Senti Biosciences beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.79M	$3.93B	$7.26B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-0.18	13.55	274.99	26.14
Price / Sales	489.68	1,209.42	582.85	87.95
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	1.75	17.17	11.22	6.33
Net Income	-$61.44M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-2.45%	-1.34%	-0.89%	-1.40%
1 Month Performance	4.73%	-8.45%	-4.42%	-3.47%
1 Year Performance	-81.40%	14.02%	7.03%	1.18%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	3.1211 of 5 stars	$0.31 -2.3%	$10.00 +3,080.7%	-83.5%	$9.79M	$20K	N/A	39
TVGN Tevogen Bio	1.4633 of 5 stars	$6.49 -1.7%	$100.00 +1,440.8%	-81.6%	$42.98M	N/A	N/A	18	News Coverage
MGX Metagenomi	3.8425 of 5 stars	$1.03 -1.0%	$6.00 +482.5%	-68.1%	$39.29M	$25.21M	N/A	113	Gap Up
EDSA Edesa Biotech	2.9763 of 5 stars	$3.72 -4.9%	$5.00 +34.4%	+34.5%	$37.70M	N/A	N/A	17	Positive News
BCTX Briacell Therap	0.6808 of 5 stars	$4.02 -3.8%	N/A	-69.1%	$36.37M	N/A	N/A	4	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. TVGN, MGX, EDSA, BCTX, and IZTC

How does Senti Biosciences compare to Tevogen Bio?

Summary

How does Senti Biosciences compare to Metagenomi?

Summary

How does Senti Biosciences compare to Edesa Biotech?

Summary

How does Senti Biosciences compare to Briacell Therap?

Summary

How does Senti Biosciences compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. TVGN, MGX, EDSA, BCTX, and IZTC

How does Senti Biosciences compare to Tevogen Bio?

Do analysts rate TVGN or SNTI?

Do insiders & institutionals hold more shares of TVGN or SNTI?

Is TVGN or SNTI more profitable?

Does the media favor TVGN or SNTI?

Which has preferable valuation and earnings, TVGN or SNTI?

Which has more volatility & risk, TVGN or SNTI?

Summary

How does Senti Biosciences compare to Metagenomi?

Do analysts rate SNTI or MGX?

Which has preferable earnings & valuation, SNTI or MGX?

Does the media refer more to SNTI or MGX?

Is SNTI or MGX more profitable?

Which has more volatility and risk, SNTI or MGX?

Do insiders and institutionals hold more shares of SNTI or MGX?

Summary

How does Senti Biosciences compare to Edesa Biotech?

Do analysts rate EDSA or SNTI?

Does the media prefer EDSA or SNTI?

Is EDSA or SNTI more profitable?

Which has more risk & volatility, EDSA or SNTI?

Do institutionals & insiders believe in EDSA or SNTI?

Which has stronger earnings and valuation, EDSA or SNTI?

Summary

How does Senti Biosciences compare to Briacell Therap?

Which has stronger valuation and earnings, BCTX or SNTI?

Do analysts rate BCTX or SNTI?

Which has more risk & volatility, BCTX or SNTI?

Do institutionals & insiders believe in BCTX or SNTI?

Does the media refer more to BCTX or SNTI?

Is BCTX or SNTI more profitable?

Summary

How does Senti Biosciences compare to Invizyne Technologies?

Do insiders & institutionals believe in IZTC or SNTI?

Does the media favor IZTC or SNTI?

Do analysts recommend IZTC or SNTI?

Is IZTC or SNTI more profitable?

Which has better earnings & valuation, IZTC or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools